Mantle Cell Lymphoma

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

Type: Multi-centre trial
Eligibility: Age <66 years Histologically confirmed (according to the WHO classification) mantle cell lymphoma stage II-IV at the time of diagnosis.  Nordic countries: high-risk patients defined by Mantle Cell Lymphoma International Prognostic Index Biological (MIPI-B), in UK all patients in need of treatment. No previous treatment for lymphoma except one cycle of any chemotherapy regimen. WHO Performance status of 0-2. Life expectancy of more than 3 months. Written informed consent.
Study details: To increase the rate of complete response and complete response unconfirmed in mantle cell lymphoma by intensified immunochemotherapy with Rituximab, High Dose Ara-C and Dexamethasone followed by BEAM in Mantle Cell Lymphoma Patients <66 Years.